Vaccitech $75 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
Davis Polk advised the sales agent in connection with a new SEC-registered at-the-marketing offering program by Vaccitech plc of its American depositary shares representing its ordinary shares under which Vaccitech may sell up to an aggregate amount of $75 million in ADSs. Vaccitech’s ADSs are listed on the Nasdaq Global Market under the symbol “VACC.”
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.
The Davis Polk capital markets team included partners Richard D. Truesdell Jr. and Marcel Fausten and associates Joze Vranicar and Michael Jiang. Partner Simon Witty and associate Vivek Thanki provided English law advice. Partner David R. Bauer and associate Alison T. Chin provided intellectual property advice. The tax team included counsel Tracy L. Matlock and associate Dmitry Dobrovolskiy. Members of the Davis Polk team are based in the New York and London offices.